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Abstract A series of novel pyrrolidin-2-one derivatives (17
compounds) with adrenolytic properties was evaluated for
antiarrhythmic, electrocardiographic and antioxidant activ-
ity. Some of them displayed antiarrhythmic activity in
barium chloride-induced arrhythmia and in the rat coronary
artery ligation-reperfusion model, and slightly decreased the
heart rate, prolonged P–Q, Q–Ti n t e r v a l sa n dQ R S
complex. Among them, compound EP-40 (1-[2-hydroxy-
3-[4-[(2-hydroxyphenyl)piperazin-1-yl]propyl]pyrrolidin-
2-one showed excellent antiarrhythmic activity. This
compound had significantly antioxidant effect, too. The
present results suggest that the antiarrhythmic effect of
compound EP-40 is related to their adrenolytic and antioxi-
dant properties. A biological activity prediction using the
PASS software shows that compound EP-35 and EP-40 can
becharacterizedbyantiischemicactivity; whereas,compound
EP-68, EP-70, EP-71 could be good tachycardia agents.
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Introduction
Now, in the globalization era, determined by speed,
uncertainty and instability people live in increasing stress
leading to rise of the incidences of cardiovascular diseases.
Cardiac arrhythmia is abnormal electrical activity in the heart,
may be caused by abnormal impulse formation, abnormal
impulse propagation, or both (Matyus et al. 1997). The most
frequently diagnosed arrhythmias with major clinical impli-
cations included heart chamber fibrillation, i.e. atrial fibril-
lation (atrial arrhythmias (AF)) and/or ventricular fibrillation
(ventricular arrhythmias (VF)) (Nattel and Carlsson 2006).
Cardiac arrhythmias remain a major source of morbidity and
mortality in developed countries. For example, between 0.5
and 1 million North Americans and Europeans die each year
of sudden cardiac death (lead to a high incidence of sudden
death in minutes to hours), which causes 10–20% of all
deaths among adults in the Western world (Goldberger et al.
2008; Huikuri et al. 2001; Kromhout 2007). It is also
estimated that if present trends continue more than 15 million
Americans will be affected by AF by 2050 (Miyasaka et al.
2006). AF is the most common arrhythmia in the population
(or the single most common factor in stroke of the elderly)
(Rich 2009) whereas VF is the most common cause of
sudden cardiac death (Elmas et al. 2008). Antiarrhythmic
drugs correct heart beats too quickly (tachycardia), too
slowly (bradycardia) or with an irregular pattern (Estrada
and Darbar 2008; Golan et al. 2008).
α1-Adrenergic receptors (α1-AR) are members of the G-
protein coupled superfamily of receptors, which modulate
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DOI 10.1007/s00210-010-0566-xintercellular biochemical processes in response to changes
in extracellular concentration of neurotransmitter norepi-
nephrine and circulating hormone epinephrine, leading to
widespread physiological actions that make them attractive
target for drug discovery. They are responsible for many
functions such as vasconstriction, inotropy, chronotropy,
blood pressure regulation, bronchodilation, sedation and
analgesia. Suppression of ARs results in vasodilation,
decreased heart rate, inotropy and relaxation of prostate
smooth muscle (Becker et al. 2004;H ee ta l .2008;
Michelotti et al. 2000; Zhong and Minneman 1999). Thus,
α1-AR antagonist can be useful in the treatment of
hypertension, benign prostatic hyperplasia, lower urinary
track symptoms or cardiac arrhythmia (Chiu et al. 2008;
Jain et al. 2008; Thiyagarajan 2002).
Our earlier research showed that some pyrrolidin-2-one
derivatives had marked significant antiarrhythmic (adrena-
line-induced) and hypotensive actives. These compounds
had affinity for α1- and α2-adrenoceptors and antagonized
the pressor response elicited by epinephrine, norepinephrine
and methoxamine. The observed effect suggested that these
compounds had adrenolytic properties (Kulig et al. 2007;
Malawska et al. 2002, 2005). Many studies implicate
adrenoceptors in the formation of arrhythmia during
myocardial ischemia and reperfusion in the isolated heart.
It was shown that α1-bloking drugs such as prazosin and
phentolamine are also effective against ischemia-induced
arrhythmias in a variety of animal models (Bernauer and
Ernenputsch 1988;B r a l e te ta l .1985; Colucci 1982;
Lamontagne et al. 1986; Tolg et al. 1997). As a continu-
ation of this study, 17 compounds (high active in
adrenaline-induced arrhythmia) were tested in model
ventricular arrhythmias associated with coronary artery
occlusion and reperfusion in the non-working isolated
perfused rat heart (Lubbe and Daries 1978) and additionally
in barium chloride-induced arrhythmia in vivo and also for
active compounds in reperfusion-induces arrhythmia
marked antioxidant activity.
Modern lead discovery and rational drug design cannot
nowadays be independent from molecular modeling which
can describe the biological activities by using theoretical
methods and computational techniques. Up to now, the
crystal structures of target of α1-ARs and arrhythmic drugs
are not known, and for this reason the study of the
interactions between the arylpiperazine derivatives and the
adrenergic or antiarrhythmic receptor can only be done by
methods of molecular modeling. Current drug discovery
methods estimate biological response of potential medicinal
agents by constructing independent and linear models.
Although these models provide a link between specific
biological targets and therapeutic effects, the properties of
natural signals are too complex to expect that an indepen-
dent set of descriptors would be capable of forecasting
biological responses. Intuitively one can imagine that the
molecules having the same scaffold ought to have similar
surface and binding affinity (or antiarrhythmic properties)
to suitable active site. However if this is truth the α1-AR
affinity and/or antiarrhythmic activity of investigated set
should differ insignificantly, which does not fit to our
pharmacological data. The (Q)SAR study was already
published (Nowaczyk et al. 2009, 2010). In this work, we
describe application of computational of biological activity
spectra according to which the compound’s biological
activity is considered as an intrinsic property of the
structure. In this context, the goal of our research was
application of computer-aided drug discovery program
Predicted Activity Spectrum for Substances (PASS) (PASS
2010; Poroikov and Filimonov 2005).
Materials and methods
Animals
The experiments were carried out on male Wistar rats (180–
250 g). Animals were housed in constant temperature
facilities exposed to 12:12 h light/dark cycle and main-
tained on a standard pellet diet and tap water given ad
libitum. All procedures were according to the Animal Care
and Use Committee Guidelines, and approved by the
Ethical Committee of Jagiellonian University, Kraków.
Control and experimental groups consisted of six to eight
animals each.
Drugs
All tested compounds (Scheme 1) were synthesized by the
doctor Katarzyna Kulig in the Department of Physicochem-
ical Drug Analysis, Pharmaceutical Faculty, Jagiellonian
University. Synthesis of tested compounds was described in
previous papers (Kulig et al. 2007).
Barium chloride (POCh, Poland), sodium heparin
(Polfa), thiopental sodium (Biochemie Gmbh, Vienna),
diphenylhydantoin sodium salt (Epanutin, Parke-Davis),
prazosin hydrochloride (Sigma–Aldrich), urapidyl (Sigma–
Aldrich), and quinidine (Sigma–Aldrich).
Ventricular arrhythmias associated with coronary artery
occlusion and reperfusion in the non-working isolated
perfused rat heart
Hearts from thiopental-anesthetised (45–60 mg/kg, ip) rats
were perfused according to the Langendorff technique
(Langendorff 1895) at constant pressure of 70 cm H2O
(6.87 kPa) with Chenoweth–Koelle solution continuously
gassed with 95% O2 plus 5% CO2 of the following
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(2.2), NaHCO3 (19.0), CaCl2 (2.4) and glucose (10.0).
The effect of tested compounds, in concentration of 10
−8
to 10
−4 M, on coronary flow (cardiac effluent), electrocar-
diogram (obtained by two stainless steel electrodes, one
inserted into the muscle of the ventricular wall and another
attached to the metal aortic cannula) were assessed after
15–20 min of initial stabilization.
Non-working isolated hearts were mounted as described
above for recording coronary flow and ECG. After a
15 min stabilization period, acute regional myocardial
ischaemia was produced for 15 min by installing a clip on
the left coronary artery close to its origin (ischaemic
period). The clip was then reopened, and changes during
reperfusion were monitored for 30 min (reperfusion period).
Occlusion and reperfusion was verified by measuring
coronary flow before occlusion, after occlusion and after
reperfusion.
Ligation of the coronary artery resulted in 24–28%
reduction in coronary flow. Reperfusion was followed by a
return of the coronary flow. Reperfusion induced arrhyth-
mias, manifested by ventricular premature beats (VBs),
ventricular tachycardia (VT) and ventricular fibrillation
(VF).
Electrocardiograms (ECGs) were analyzed according to
the guidelines of the Lambeth Conventions for VBs,
bigeminy, salvos (less than four successive VBs), ventric-
ular tachycardia (VT, four or more successive VBs) and
ventricular fibrillation (VF).
In order to obtain a measure for the intensity of the
arrhythmias, an Arrhythmia Severity Index was calculated
for each heart according to Bernauer (Bernauer and
Ernenputsch 1988): the occurrence of up to ten ventricular
extrasystoles during the first 30 min of reperfusion was
attributed the value 1, more than ten the value 2, ventricular
tachycardia or ventricular flutter the value 3, and ventricular
fibrillation the value 4. Bigeminy and salvos were not
quantified separately but included with VBs.
Agents were added to the perfusion medium 15 min
before coronary artery ligation and the concentration was
maintained for the rest of the perfusion period.
Prophylactic antiarrhythmic activity in barium
chloride-induced arrhythmia acc. to Szekeres
(Szekeres and Papp 1975)
Barium chloride solution was injected into the caudal vein of
rat (32 mg/kg, ina volumeof1 ml/kg).The testedcompounds
Scheme 1 Schematic structure of new pyrrolidin-2-one derivatives
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antiarrhytmic activity was a gradual disappearance of the
arrhythmia and restoration of the sinus rhythm.
Antioxidant effect—measurement of lipid peroxidation
in rat brain homogenate (Yue et al. 1992)
The ratbrainhomogenatewas madein0.9%salinecontaining
10 mg tissue/ml. The rates of membrane lipid peroxidation
weremeasuredbytheformationofthiobarbituricacidreactive
substance (TBARS). Rat brain homogenates (1 ml) were
incubated at 37°C for 5 min with 10 μl of a test compound or
vehicle. Lipid peroxidation was initiated by the addition of
50 μl of 0.5 mM FeCl2 and 50 μl of 2 mM ascorbic acid.
After 30 min of incubation, the reaction was stopped by
adding 0.1 ml of 0.2% BHT. Thiobarbituric acid reagent was
then added and the mixture was heated for 15 min in a boiling
water bath. The TBARS was extracted by n-butanol and
measured at 532 nm. The amount of TBARS was quantified
using a standard curve of MDA as described previously.
Statistical analysis
The data are expressed as the means±SEM or percent. The
data were evaluated by one-way analysis of variance
followed by Duncan’s test or Fisher’s test; p<0.05 was
considered significant.
Computational methods
The computational procedure applied in this study includes:
1. For the molecular 3D structure calculations the
Gaussian® 03 (version 6.1) package was used (Frisch
et al. 2004). The three-dimensional structures of the
pyrrolidin-2-one derivatives at their neutral state were
obtained through full optimization based on the AM1
quantum chemical procedure. Force field calculations
were used to ascertain whether the resulting structures
were true energy minima. All the molecules were
minimized until the root mean square gradient value
became smaller than 10
−6 a.u.
2. Form 3D structure geometry-optimized data generated
from Gaussian 03 were create MOL-files use the
GaussView 4.1 program (GaussView 2003). Later,
MOL-files, were submit individually to the internet
version of PASS program and obtain the predicted
biological activity spectrum (for prediction activity (Pa)
>prediction inactivity (Pi) and Pa>0.5).
3. From then full activity spectrum calculated by PASS
system our analysis was limited to narrow topic related
to cardiovascular diseases such as: Tachycardia, Anti-
ischemic, Antiarrhythmic, Cardiotonic.
Results
Ventricular arrhythmias associated with coronary artery
occlusion and reperfusion in the non-working isolated
perfused rat heart
Ligation of the coronary artery resulted in a 35–40%
reduction in coronary flow. Reperfusion was followed by a
return of the coronary flow to 80–100% of the preocclusion
values. Reperfusion induced arrhythmias, which manifested
by VBs, VT and VF.
During the 30 min period of coronary artery reperfusion,
all hearts in the control group developed VBs. The
incidence of VT and VF was 60 and 50%, respectively
(Tables 1 and 2).
Compared with control hearts, only five compounds
(EP-40, EP-44, EP-46, EP-70 and EP-71) significantly
diminished the incidence of ventricular tachycardia and
ventricular fibrillation (Tables 1 and 2).
The most potent antiarrhythmic effect was produced by
compound EP-40, which significantly reduced the incidence
of: VBs (50%), VT (about 20–40%) and VF (40%) in
concentration 10
−5−10
−4 M. The arrhythmias severity index
was lower (2.7–3.4), compared with control hearts (5.4).
Compounds: EP-44, EP-46, EP-70 and EP-71 showed
weaker antiarrhythmic effect in this model. This compound
significantly reduced the incidence of VT and VF in
concentration 10
−5 only. In this concentration, their
arrhythmias severity index was similar and had a value
about 3.0–3.3.
Remaining compounds, used in concentrations of 10
−6−
10
−4 M, did not show antiarrhythmic activity in this test.
Reference drugs in this model : phenytoin and quinidine
(I class Vaughan Williams classification), (Vaughan Williams
1975, 1981) showed significantly effect in this test in
concentrations 10
−5 (phenytoin) and 10
−6−5×10
−6 (quinidine)
(Table 2). Alpha adrenolityc drugs: prazosin and urapidyl
showed significantly affect only in concentrations 10
−6 M
(Table 2).
Influence of active tested compounds on ECG parameters
on the non-working isolated perfused rat heart
The five active tested compounds (EP-40, EP-44, EP-46,
EP-70, and EP-71) decreased the number of cardiac beats
per minute, prolonged P–Q, Q–T, intervals and QRS
complex. The QTc was calculated according to the formulae
of Bazzett: QTc=Q–T/√RR.
All compounds in concentration 10
−6−10
−4 Ms i g n i f i c a n t -
ly decreased the number of cardiac beats per minute
(10
−6 M, 9–16%; 10
−4 M, 18–24%). This chronotropic
effect was similar to phenytoin (10
−6 M, 11%; 10
−4 M, 21%)
and weaker to quinidine (10
−7 M, 10
−4 M, 17–35%) (Fig. 1).
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−6−10
−4 M
significantly prolonged P–Q intervals (10
−6 M, 15–28%;
10
−4 M, 38–48%), Q–Ti n t e r v a l s( 1 0
−6 M, 15–25%;
10
−4 M, 28–41%) and QRS complex (10
−6 M, 12–21%;
10
−4 M, 26–33%), (Figs. 2, 3, and 4). The electrocardio-
graphic changes observed after administration of the tested
compounds were weaker to those observed for quinidine.
Phenytoin similar prolonged P–Q and Q–T interval, but did
not change the QRS complex, (Figs. 1, 2, 3,a n d4). The
changes of QTc were similar to those seen after adminis-
tration of phenytoine (10
−5 M, 11–16%; 10
−4 M, 13–
18%). The strongest effect of QTc was revealed by
quinidine (10
−6 M, 19%; 10
−4 M, 70%). The obtained
results suggest that the new pirrolidin-2-ones derivatives
possesses “quinidine-like” properties.
Prophylactic antiarrhythmic activity in barium
chloride-induced arrhythmia
For examined rats, intravenous injections of high dose of
barium chloride (32 mg/kg) caused a rapid ventricular
extrasystoles and ventricular fibrillation at all animals
Table 1 Effect of tested compounds on reperfusion-induced arrhythmias
Compound Concentration
(M)
VBs incidence
(%)
Bigeminy
incidence (%)
Salvos
incidence (%)
VT incidence
(%)
VF incidence
(%)
Arrhytmias
severity index
Control – 100 50 30 60 50 5.4±0.6
EP-24 10
−6 80 40 20 50 30 4.9±0.8
10
−5 80 50 20 50 25 4.5±0.9
10
−4 100 40 30 50 40 4.8±0.6
EP-26 10
−6 80 50 40 40 60 5.4±1.1
10
−5 60 50 30 60 40 4.8±1.2
10
−4 75 50 25 50 75 5.5±0.3
EP-28 10
−6 100 80 20 60 50 5.4±0.7
10
−5 100 80 40 60 50 5.4±0.7
10
−4 100 80 40 60 80 6.0±0.8
EP-32 10
−6 100 50 40 62.5 37.5 5.0±0.8
10
−5 100 25 25 62.5 25 4.5±0.5
10
−4 100 50 25 75 25 5.0±0.2
EP-35 10
−6 100 25 12.5 75 25 5.1±0.2
10
−5 87.7 12.5 12.5 62.5 25 4.5±0.7
10
−4 87.7 12.5 12.5 62.5 37.5 5.0±0.3
EP-40 10
−6 60 25 0 40 20 4.1±0.7
10
−5 50 25 0 20 10 2.7±0.4**
10
−4 50 50 0 40 10 3.4±0.6*
EP-41 10
−6 87.7 12.5 12.5 62.5 25 4.5±0.7
10
−5 87.7 12.5 12.5 62.5 25 4.5±0.7
10
−4 100 50 25 75 25 5.0±0.2
EP-43 10
−6 100 10 10 66 33 5.2±1.2
10
−5 80 10 0 40 30 3.8±0.6
10
−4 100 50 25 50 33 4.6±1.1
EP-44 10
−6 100 50 17 50 33 4.5±0.6
10
−5 100 33 17 33 17 3.3±0.7*
10
−4 100 50 17 50 17 3.8±0.8
EP-46 10
−6 87.7 33 33 66.4 17 4.2±1.1
10
−5 87.7 17 17 50 0 3.2±0.9*
10
−4 100 33 17 50 33 4.8±0.6
EP-47 10
−6 100 60 20 40 40 4.8±0.7
10
−5 100 40 20 20 40 4.2±0.9
10
−4 100 80 40 20 40 4.2±0.9
Each value was obtained from six to eight hearts
*p<0.05; **p<0.02 (significantly different to control)
Naunyn-Schmied Arch Pharmacol (2011) 383:13–25 17(100%), which led to the death within 3–8 min. The tested
compounds were given intravenously 15 min before
arrhythmogen (Figs. 5 and 6).
The highest activity was demonstrated by compound EP-
40, which reduced incidence of ventricular fibrillation (by
50%) and decreased number of extrasystoles (by 33%) in
doses 10 and 20 mg/kg. In these doses, it protected the
animals against death, too (by 50%). Compounds EP-46
and EP-70 inhibited occurrence of ventricular fibrillation in
50%, but only in dose 20 mg/kg. This compounds
decreased number of extrasystoles in 25%. Compound
EP-70 reduced mortality of tested animals in 50%. Com-
pounds EP-24, EP-26, EP-32, EP-35, EP-41, EP-43, EP-44,
EP-47, EP-67, EP-68, EP-69, EP-71, and EP-74 possessed
weak antiarrhythmic properties, reduced incidence of
ventricular fibrillation in 10–40% (Table 3).
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Fig. 1 Influence of active tested compounds on heart rate
Table 2 Effect of tested compounds, phenytoin, quinidine, urapidyl, and prazosin on reperfusion-induced arrhythmias
Compound Concentration
(M)
VBs incidence
(%)
Bigeminy
incidence (%)
Salvos
incidence (%)
VT incidence
(%)
VF incidence
(%)
Arrhytmias
severity index
Control – 100 50 30 60 50 5.4±0.6
EP-67 10
−6 100 25 0 75 50 6.0±0.7
10
−5 100 25 0 50 25 4.5±0.8
10
−4 100 50 0 75 25 5.2±0.2
EP-68 10
−6 100 75 25 50 50 5.5±1.4
10
−5 100 50 25 50 50 5.5±1.4
10
−4 100 50 25 50 25 4.5±0.9
EP-69 10
−6 100 50 50 75 25 5.2±0.2
10
−5 100 0 0 50 25 4.5±0.8
10
−4 100 0 0 50 25 4.5±0.8
EP-70 10
−6 100 17 17 66.4 33 5.2±0.9
10
−5 100 17 0 33 17 3.2±0.7*
10
−4 100 50 0 50 33 4.5±1.0
EP-71 10
−6 100 50 17 33 33 4.0±0.7
10
−5 87.7 17 0 33 17 3.0±0.8*
10
−4 100 50 33 50 17 3.8±0.6
EP-74 10
−6 100 75 25 75 50 6.2±0.9
10
−5 100 75 0 75 25 5.2±0.2
10
−4 100 50 0 50 50 5.5±0.3
Phenytoin 10
−6 100 0 0 75 0 4.3±0.3
10
−5 100 0 0 25 0 2.6±0.4**
10
−4 100 25 0 40 20 4.1±0.7
Quinidine 10
−6 83.3 16.7 0 50 0 2.3±0.76*
5×10
−6 16.7 0 0 33.3 0 1.2±0.6***
Urapidyl 10
−6 90 25 0 25 12.5 3.6±0.2*
10
−5 100 50 0 50 40 4.9±0.3
Prazosin 10
−6 60 0 0 23.5 10 2.8±0.6**
10
−5 90 0 0 50 30 4.0±0.6
Each value was obtained from six to eight hearts
*p<0.05; **p<0.02; ***p<0.001 (significantly different to control)
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ventricular fibrillation in 34% and reduced mortality of
tested animals in 64% and phenytoin (in dose 10 mg/kg)
inhibited occurrence of ventricular fibrillation in 31% and
reduced mortality of tested animals in 56% (Table 3).
Urapidyl and prazosin (α-blocking agents) administered
15 min before barium chloride, did not change the
occurrence of disturbances, but it slightly reduced the
number of premature ventricular beats.
Antioxidant effect—measurement of lipid peroxidation
in rat brain homogenate
The antioxidant effect was studied for five compounds,
active in model reperfusion-induced arrhythmias: EP-40,
EP-44, EP-46, EP-70, and EP-71. In this experiment,
only compound EP-40 significantly inhibited Fe
2+-initi-
ated lipid peroxidation, measured as TBARS, in rat brain
homogenate.
Molecular modeling results
The biological activities of the 17 analogues of 1-(3-(4-
arylpiperazin-1-yl)-propyl)-pyrrolidin-2-ones were pre-
dicted individually by the software PASS. Furthermore, a
literature survey revealed two new arylpiperazine arrhyth-
mic drugs: the RSD992 (Hayes et al. 2002) and RS87337
(Dumez et al. 1989). These arylpiperazine compounds
(structurally like our molecule) exhibited significant pro-
tection against isochemic arrhythmias in rat models. These
agents were found to possess an electrophysiologic profile
characteristic of both classes I and III (mixed sodium/
potassium channels blocking properties). RSD922
exhibited characteristics of an isochaemia-selective and
frequency-dependent sodium channel blocker and fully
protected rats from isochaemia-included arrhythmias
(Hayes et al. 2002). The RS87337 exhibit unusual
combination of classes III and I activity may be effective
against re-entry phenomena such as occur in atrial fluter.
Administration of RS87337 significantly reduced the
incidence of fibrillation and death (Dumez et al. 1989).
All of these actions suggest that compounds like RSD992
and RS87337 could be effective in treatment of several
types of arrhythmia. In this context structure of the RSD992
and RS87337 were chosen for predicted the biological
activity by PASS as a reference for class I and III. All
computations were performed by computer system PASS
server (http://www.ibmh.msk.su/PASS). Traditional QSAR
and 3D molecular modeling methods are successful at
predicting the biological activities for chemical structures,
for small number of types of activity. In reality many
biologically active compounds possess several types of
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Fig. 5 Influence of active tested compounds on Q–Tc intervals
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Fig. 4 Influence of active tested compounds on Q–T intervals
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Fig. 3 Influence of active tested compounds on QRS complex
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Fig. 2 Influence of active tested compounds on P–Q intervals
Naunyn-Schmied Arch Pharmacol (2011) 383:13–25 19activity. The PASS system is able to predict many types of
activity for a substance (predicts simultaneously several
hundreds of various biological activities). The current
version of PASS predicts simultaneously 3,678 biological
activity types for 46,000 compounds including pharmaco-
therapeutic effects, mechanisms of action, interaction with
drug-metabolizing enzymes, side effects, and toxicity.
PASS system gives only qualitative information of certain
compound activity in specific activity. The results consist
only of Pa or Pi, which are the estimates of probability for
the compound to be active and/or inactive in each type of
activity from the biological activity spectrum. Computed
values vary within the range of 0.0–1.0. Activities with Pa
>Pi are considered as possible for a particular compound.
In the case of Pa>0.7, the expectation of activity and the
chance of being the analogue of the known pharmaceutical
agents for this compound are high. By the contrary, Pa<0.7
indicates that compound is not so similar to the known
pharmaceutical agents and its activity must be considered
less probable. Detailed description of these software can be
found on the web-site (PASS) and its applications can be
found in the literature (Fleisher et al. 2009; Gholivand et al.
2009; Marwaha et al. 2007; Poroikov and Filimonov 2005;
Poroikov et al. 2000). In this work, we have limited the
prediction with following parameters: Pa>Pi and Pa>0.5.
In Table 4, we have limited the number of presented
activities to these of the cardiac relationship of the whole
activity spectra set. According to the results, the prediction
of the activity as tachycardia by compound EP-68, EP-70,
EP-71 and antiischemic by compounds: EP-35, EP-40 and
RS87337 are high (Pa≥0.7). Remarkably high probable
(Pa≥0.9) of the mechanisms of antiarrhythmic action poses
compounds EP-41, EP-43, EP-44, EP-46. Similarly high
probability (Pa≥90) was found for mechanisms of cardio-
tonic action in compounds EP-43, EP-47, EP-67.
Discussion
The existence of α1-AR in the human heart has been
proven using molecular biology, biochemical methods and
functional studies (Brodde et al. 2006; Salvi 2001). Even
though it is well recognized that β-adrenergic receptor (β-
AR) stimulation markedly increases the contractility of
human myocardium, the role of myocardial α-adrenergic
receptors (α-AR) in mediating the positive inotropic effect
of catecholamines in humans is not known (Landzberg et
al. 1991). It was found that this subtype of the receptors is
quite rare in the human heart and as yet it is not well
characterized (Brodde et al. 2006). Cardiomyocytes of all
mammalian species express all subtype of α1-AR, even if
their numbers represent only 25% to those of β-
adrenoreceptors. However, in the failing human heart, there
is a down regulation of β-AR while the number of α-AR is
unchanged. Cardiomyocytes exposed to acute ischemia for
as short as 10 min have been shown to exhibit a two- to
threefold increase in the numbers of α1-adrenoreceptors
(Salvi 2001). Therefore, the more β-AR are reduced in
serve heart failure, the more important α-AR mediated
positively inotropic effect might become to maintain
cardiac contractility (Bohm et al. 1988). The α-AR are
present in both normal and failing human left ventricular
myocardium and mediate a positive inotropic effect in
several other species; it is not known whether stimulation of
myocardial α-AR exerts a positive inotropic effect or
contributes to basal contractile state in vivo in humans.
α1-AR receptors play an important role in cardiac growth in
the children and in the adult heart they inhibit the
generation of atrial and ventricular arrhythmias. Stimulation
(in vivo, in humans) of myocardial α1-AR receptors
increases contractility (Landzberg et al. 1991). The myo-
cardial α1-adrenergic receptors are functionally active in
humans may also have implications for other actions of the
myocardial α1-adrenergic receptor.
It is known that most pyrrolidin-2-one derivatives
displayed affinity for α1- and α2-adrenoceptors and strong
antiarrhythmic and hypotensive activity (Kulig et al. 2007).
Based on these data, now the antiarrhythmic activity of
novel pyrrolidin-2-one derivatives with adrenolytic proper-
ties was examined in arrhythmia associated with coronary
artery occlusion and reperfusion in the non-working
isolated perfused rat heart and in barium chloride-induced
arrhythmia.
Many authors suggest that the rat coronary artery
ligation and reperfusion model can be recommended as a
screen for new antiarrhythmic agents (Starmer et al. 1991;
Brooks et al. 1989; Curtis et al. 1987; Uematsu et al. 1986;
Walker et al. 1988). Re-opening of the occluded left
coronary artery led to arrhythmias which began almost
immediately after the coronary flow was restored. The
control
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Fig. 6 Antioxidant effect of tested compounds
20 Naunyn-Schmied Arch Pharmacol (2011) 383:13–25importance role in the genesis of ventricular arrhythmias
associated with coronary artery occlusion and reperfusion
plays the products of hypoxic metabolism and reperfusion
of ischemic myocardium. These products include locally
released catecholamines, potassium, thromboxane and
oxygen-derived free radicals (Bernier et al. 1989; Bralet et
al. 1985; Curtis et al. 1987; Page et al. 2002; Rohilla et al.
2010) concluded that inhibitors of the fast inward current
(class I agents) and inhibitors of the inward current (class
IV agents) appear to be particularly effective antiarrhyth-
mics in rats against both ischemia- and reperfusion-induced
arrhythmias.
The five tested compounds (EP-40, EP-44, EP-46, EP-70,
and EP-71) exhibited antiarrhythmic effects, in arrhythmia
associated with coronary artery occlusion and reperfusion rat
modelsbutthestrogest effect was revealed by compound EP-
40, (Tables 1 and 2). The antiarrhythmic activity of
compound EP-40 in this test was comparable to that
reported for phenytoin, urapidyl and prazosin. Binding
studies presented in the previous papers (Kulig et al. 2007;
Malawska et al. 2002, 2005) showed that compound EP-40
had affinity for α1 - and α2 -adrenoceptors (α1-Ki=194 nM;
α2-Ki=2260 nM) and antagonized the pressor response
elicited by epinephrine, norepinephrine and methoxamine.
The observed effect suggested that these compounds had
adrenolytic properties, preferential to α1-adrenoceptors.
It has been well known that α-blocking agents (phen-
tolamine, prazosin, corynanthine, rauwolscine and yohim-
bine) in relatively high doses diminished or prevented
reperfusion arrhytmias and cardiac arrhythmias caused by
Table 3 Prophylactic antiarrhytmic activity in barium chloride-induced arrhythmia
Compound Dose (mg/kg) Extrasystoles reduce (%) Ventricular fibrillation reduce (%) Mortality reduce (%)
EP-24 20 20 20 20
EP-26 40 40 50*
EP-28 20 0 20
EP-32 0 20 20
EP-35 0 20 20
EP-40 20 33 50* 50*
10 33 50* 50*
51 7 0 1 7
EP-41 20 17 0 17
10 40 17 50*
51 7 0 1 7
EP-43 20 20 25 20
10 10 0 10
50 0 0
EP-44 20 0 17 50*
10 33 33 33
5 33 17 50*
EP-46 20 25 50* 25
10 10 20 20
EP-47 20 20 20 20
10 0 20 20
5 0 20 0
EP-67 20 0 10 20
EP-68 17 17 0
EP-69 20 20 10
EP-70 20 25 50* 50*
10 20 25 50*
EP-71 20 25 25 25
10 0 25 25
EP-74 20 17 17 33
Quinidine 15 34 34 64*
Phenytoin 10 27 31 56*
*p<0.05 (significantly different to control)
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Bralet et al. 1985; Colucci 1982; Lamontagne et al. 1986;
Tolg et al. 1997). Phentolamine, a non-selective blocker of
α1- and α2-adrenoceptors, and the selective α1-adrenocep-
tor antagonist prazosin could reduce the incidence of
ischemia-induced ventricular fibrillation, which is in accor-
dance with several studies in the ischemic or reperfused rat,
cat and dog myocardium (Corr et al. 1978, 1981, 1986;
Corr and Witkowski 1984; Stewart et al. 1980; Sheridan et
al. 1980; Sharma et al. 1983; Thandroyen et al. 1983;
Benfey et al. 1984; Heusch 1990).
Out of five tested derivatives, only EP-40 had signifi-
cantly antioxidant effect. Oxygen free radicals have been
implicated in myocadial damage during ischemic insults,
and especially during the initiation of reperfusion (Yue et
al. 1992). Oxygen free radicals play the importance role in
the genesis of ventricular arrhythmias associated with
coronary artery occlusion and reperfusion (Bernier et al.
1989;B r a l e te ta l .1985). The importance of oxygen
radicals in ischemic myocardial damage is further sup-
ported by the protective effect of antioxidans such as
U74500A, a 21-aminosteroid (lazaroid), (Yue et al. 1992).
Only compound EP-40 administered 15 min before
barium chloride in dose of 10 mg/kg it prevented in a
statistically significant manner the occurrence of ventricular
fibrillation in 50%. This effect was higher than the
antiarrhythmic effect of phenytoin and quinidine in the
barium chloride model of arrhythmia. Barium ions decrease
the outward potassium currents across blocking the ultra-
rapid delayed rectifier K
+ channels and inwardly rectifying
K
+ channels (Kir), pacemaker K
+ channels (IK), back-
ground K
+ channels (IK1), Ach-induced K
+ current (IK,ACh),
calcium-activated K
+ channels (ICa) and ATP-sensitive K
+
channels (IK,ATP), fatty acids-activated K
+ channels (IAA),
(Boyett et al. 1996; Carmeliet 1999). Blocking of potassium
channels by barium ions cause rapid diastolic depolariza-
tion and initiation of spontaneous repetitive activity by
mechanisms of early afterdepolarizations and spontaneous
phase 4 depolarization (abnormal automaticity) (Ino et al.
1995). As a consequence of its K
+ chanel-blocking action,
barium prolongs Q–T interval. It known that, antiarrhyth-
mic drugs (lidocaine, phenytoin), which blocking Na
+
channel, reduce the Na
+ current and abolish early and
delayed afterdepolarization (EADs and DADs). It is of
interest to note that α-antagonists (phentolamine, prazosin,
and yohimbine) blocked the fast sodium channels in
manner similar to that displayed by lignocaine or quinidine
(Northover 1983).
Additionally, in our earlier research EP-40 showed the
weak local-anesthetic activity—which is possible by block-
ing the fast sodium channels.
Preliminary pharmacological experiment in vitro showed
that compound EP-40 (similarly: EP-44, EP-46, EP-70 and
EP-71) slightly decreased the heart rate, and prolonged the
P–Q, Q–T intervals and QRS complex. The changes in
ECG were similar but a lot weaker comparing to the
Compounds Tachycardia
a Antiischemic
a Cardiotonic
b Antiarrhytmic
b
Pa Pi Pa Pi Pa Pi Pa Pi
EP-24 0.664 0.020
EP-26 0.604 0.033 0.532 0.005
EP-28 0.631 0.027 0.595 0.005
EP-32 0.663 0.020 0.502 0.005
EP-35 0.603 0.0662 0.704 0.015 0.909 0.004 0.780 0.004
EP-40 0.528 0.107 0.737 0.012 0.892 0.004 0.614 0.005
EP-41 0.609 0.059 0.589 0.038 0.985 0.004 0.928 0.004
EP-43 0.634 0.026 0.980 0.004 0.911 0.004
EP-44 0.546 0.096 0.599 0.035 0.987 0.003 0.934 0.003
EP-46 0.618 0.054 0.565 0.046 0.982 0.003 0.923 0.004
EP-47 0.537 0.102 0.546 0.052 0.960 0.004 0.874 0.004
EP-67 0.588 0.070 0.565 0.046 0.938 0.004 0.836 0.004
EP-68 0.757 0.019 0.633 0.026
EP-69 0.633 0.047 0.572 0.043 0.600 0.006
EP-70 0.725 0.023 0.580 0.041 0.709 0.004 0.709 0.004
EP-71 0.713 0.025 0.601 0.034 0.575 0.008
EP-74 0.670 0.035 0.612 0.031 0.705 0.004
RDS992 0.566 0.084 0.590 0.038
RS87337 0.697 0.016
Table 4 The probabilities of
being active Pa of the test com-
pounds on the basis of PASS
prediction
Pa predictive activity values, Pi
predictive inactivity values
aPredictive biological activities
bPredictive mechanisms
of action
[N-(3,5-dichlorophenyl)-4-
(4-hydroxy-2-methoxyphenyl)-
1-piperazinecarboxamidine
22 Naunyn-Schmied Arch Pharmacol (2011) 383:13–25quinidine. Additionally these compounds did not prolong
significantly the calculated interval QTc (Bazzett formulae)
as opposed to the quinidine. This is very essential because
compounds which prolong significantly calculated interval
QTc can have proarrhythmic proprieties (Clerck et al. 2002;
Crumb and Cavero 1999). Due to the pharmacological data
presented above suggest that the antiarrhythmic effect of
compound EP-40 (1-[2-hydroxy-3-[4-[(2-hydroxyphenyl)
piperazin-1-yl]propyl]pyrrolidin-2-one may be related to
their α-adrenolytic and antioxidant properties.
The principle of structure-activity relationships (SAR)
theory is assumption that similar molecule suppose to have
similar activities. Consequently the SAR study is focused
on discovery which parts of the molecule are important to
biological activity and which are not. Additionally,
information about significant structure features (essential
groups of a molecule) open opportunity for generating
more knowledge (explanation and understanding) about
particular biological responses. According to PASS pre-
dictions, shown in Table 4, EP-70 and EP-71 should have
tachycardic activity. This indicates that compounds EP-70
and EP-71 may occur to be a close analogue of known
pharmaceutical tachycardic agents. Furthermore, in both
cases this activity was found experimentally and is
accompained by significantly diminished incidence of
vascular tachycardia and ventricular fibrillation. Com-
pounds EP-35, EP-40 according to PASS prediction is
probably highly similar structurally to known antiischemic
agents and supposes to have antiischemic activity. But the
antiarrhytmic activity in the ischemia-reperfusion model
was found in EP-40 only. These two systems differ in
structure by the substituent at position 2 at aryl ring (for
EP-35 it is F and for EP-40 OH group).
Rational drug discovery methods estimate biological
response of potential medicinal agents by steric effects and
variety of specific and nonspecific intermolecular interac-
tions such as: hydrogen bonding, ionic interactions,
hydrophobic interactions, Van der Waals interactions or
some combinations of them. Considering the differences in
the structure of compounds EP-35 and EP-40 one should
thoroughly focused on chemical properties of the aryl part.
The type of substituent on phenyl ring markedly influences
the properties of the compound including the biological
activities. While EP-35 and EP-40 differ only in the
substituent at position 2 of the phenyl ring (F and OH,
respectively) it is important to discus few general features
of these moiety. It is well known that unsubstituted benzene
(sometimes abbreviated Ph–H) is perfectly planar. The
electrostatic potential surface obtained from quantum
mechanical calculations shows the build-up of negative
electrostatic potential in the center of the carbon ring
surrounded by positive electrostatic potential localized on
hydrogen atoms. Ph–H shows a hydrophobic and slightly
polar properties due to the nature of its π-electron system
that acts as a weak hydrogen bond acceptor. Many
important chemicals are derived from Ph–H by replacing
one or more of its hydrogen atoms with another functional
group. Fluorine is considered as isosteric with hydrogen
(the van der Waals radius about 20% larger than that of H).
According to this, when C–H bond of the substrate is
replaced with a C–F bond it is expected not to exert a
confounding steric influence (so called “mimic effect” of F
for H). Fluorobenzene like benzene is planar molecule. In
view of the fact that fluorine is the most electronegative
element, it is expected that groups containing fluorine have
unique inductive effects on the physicochemical properties
of the molecules bearing them. Fluorine can share three sets
of lone—pair electrons with electron—deficient atoms
intramolecularly or intermolecularly. Thus, when fluorine
is incorporated into bioactive compounds, these substitu-
ents will influence strong effects on the binding affinity for
the receptors or target enzymes, biological activities, and
pharmacokinetics. Replacement of a specific C–H bond
with a C–F bond can effectively block metabolic processes
via hydroxylation of C–H bonds, predominantly by the
cytochrome P-450 family of enzymes (so called “block
effect”). Due to incorporation of fluorine(s) into metabo-
lism site(s) has been widely used to prevent deactivation of
biologically active substances in vivo. It has recently been
shown that polar C–F bond—protein interactions play a
critical role in the stabilization of fluorine—containing
drugs and their target proteins. The majority of examples
(include those between a C–F bond and polar functional
groups) from the protein crystallographic database indicate
that a C–F bond unit serves as a poor hydrogen-bond
acceptor. It is also well known that incorporation of halogen
groups increases the lipophilicity of organic compounds,
especially aromatic compounds. Nevertheless, fluoroben-
zene (log P≈2.27) is slightly more lipophilic than benzene
(log P≈2.13), but in contrast chlorobenzene is much more
lipophilic log P=2.84).
In the case of compound EP-40, the Ph–Hb o n di sr e p l a c e d
with the Ph–OH bond. The introduction of hydroxy groups
into the structure of a lead will normally produce analogues
with an increased hydrophilic nature and low lipid solubility.
It also provides a new center of hydrogen bonding, which
could influence the binding of the analogue to its target site.
Ph-OH like Ph–Ha n dP h –F have planar geometry. Due to
resonance stabilization Ph-OH moiety is highly acidic,
because it has a partial positive charge on the oxygen atom
(three of the four contributing resonance structures possess a
positive charge on the oxygen atom of the molecule). The
effect of aromatic ring substituent on a receptor binding
affinity of a parent structure could be interpreted in terms of
the hydrogen binding donor and acceptor ability. The Ph–OH
hydroxyl group can act as hydrogen bond acceptor. Increase
Naunyn-Schmied Arch Pharmacol (2011) 383:13–25 23of hydrogen - bond accepting capability of the compound,
effect the decrease in hydrophobicity and thus lipophilicity
(log P of Ph–OH≈1.51). All above facts suggests that
hydrophobicity and hydrogen bond acceptor capacity of
arylpiperazine moiety play significant role in the antiarrhyth-
mic action. Additionally, in case of EP-40 it was experimen-
tallyproventhatprolongationofQ–Tinterval,whichsuggests
that the antiarrhythmic action can be related to class I/III.
Consequently we assume that electrophysiologic profile of
EP-40 is similar to RS87337 (Dumez et al. 1989).
Base on results presented above (both experimental and
calculations) one can draw the hypothesis that compound EP-
40 possesses the affinity to cardiac Na
+ and K
+ channels
(similar to class I/III antiarrhythmic agents). The limited
scope of this study does not however allow us to confirm or
deny the possibility that EP-40 may have ischaemia-selective
actions on repolarization and refractoriness through actions
on other systems, but this needs further research.
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